MGFA has partnered with Bionews to feature the Myasthenia Gravis News feed on our website, providing the community with research updates, disease management insights, and relevant news. All content is original and produced by Bionews’ editorial staff, and perspectives from patients and caregivers. Information is not meant to replace or provide medical advice.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- MDA Engage: ‘I am not alone’ was the biggest takeaway in Chicago
by Douglas Backstrom on October 2, 2026 at 2:24 pmFor many people living with rare neuromuscular diseases, the most meaningful part of a recent Chicago gathering was not just the medical updates — it was finding a community that understood their daily struggles. The realization that they were not alone set the tone for MDA Engage: Chicago, a free symposium held Sept. 26 in The post MDA Engage: ‘I am not alone’ was the biggest takeaway in Chicago appeared first on Myasthenia Gravis News.
- Living with myasthenia gravis makes me skilled at the art of anticipation
by Sarah Bendiff on October 1, 2026 at 2:00 pmI recently heard myself saying that going on vacation was simply not an option for me. I was craving some rest, though, and saying it made me sad to realize that I wasn’t dismissing the idea because of my job or family arrangements, but because of living with myasthenia gravis (MG). Sometimes, I have to The post Living with myasthenia gravis makes me skilled at the art of anticipation appeared first on Myasthenia Gravis News.
- MGFA Session 2026: Treatment cuts gMG hospitalization rates
by Lindsey Shapiro, PhD on October 1, 2026 at 12:00 pmRegeneron Pharmaceuticals’ investigational therapy cemdisiran significantly reduced hospitalization rates among people with generalized myasthenia gravis (gMG) in a global clinical trial. The data from the Phase 3 NIMBLE study (NCT05070858) were presented by trial investigator Ali Habib, MD, a neurologist at the University of California, Irvine, at the Myasthenia Gravis Foundation of America (MGFA) scientific The post MGFA Session 2026: Treatment cuts gMG hospitalization rates appeared first on Myasthenia Gravis News.
- Minor cuts and infusion delays leave me worn down as I navigate MG
by Mark Harrington on September 30, 2026 at 2:00 pmA few weeks ago I cut my left hand while chopping food. I gave the wound little thought. It became infected, and, rather stupidly, I ignored it, as if a problem might go away if I refused to look at it. I knew better. People living with myasthenia gravis (MG), especially those on corticosteroids, have The post Minor cuts and infusion delays leave me worn down as I navigate MG appeared first on Myasthenia Gravis News.
- MGFA Session 2026: Single CAR T-cell therapy dose eases gMG up to 1.5 years
by Lindsey Shapiro, PhD on September 30, 2026 at 1:30 pmA single dose of Kyverna Therapeutics’ experimental CAR T-cell therapy mivocabtagene autoleucel (miv-cel) led to reductions in symptom severity among people with difficult-to-treat generalized myasthenia gravis (gMG) that have been sustained for up to 1.5 years. Importantly, most participants reached a state where their gMG symptoms have little to no impact on their daily lives The post MGFA Session 2026: Single CAR T-cell therapy dose eases gMG up to 1.5 years appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.
